Iambic Therapeutics, Inc.
No SEC Form 4 filings for $IAM in the last 30 days.
See all $IAM insider activity →Iambic Therapeutics Inc., an AI-driven biotech firm backed by Nvidia, saw its shares rise 16% in its IPO debut, trading at $18.50 after raising $150 million. The company, which focuses on cancer drug discovery, now has a market value of $877 million. Proceeds will advance three early-stage drug candidates. Key investors include ARK Investment Management and Stanley Druckenmiller's Duquesne Family Office.
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning IAM (Iambic Therapeutics, Inc.). Coverage has skewed bullish: 7 bullish, 0 neutral, and 1 bearish.
IPO pricing and first-day trading momentum likely drive near-term volatility and positioning around the new float.
AlphAI scores every news story that mentions IAM with an AI model for sentiment and relevance, and aggregates insider trades from Iambic Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Iambic Therapeutics Inc., an AI-driven biotech firm backed by Nvidia, saw its shares rise 16% in its IPO debut, trading at $18.50 after raising $150 million. The company, which focuses on cancer drug discovery, now has a market value of $877 million. Proceeds will advance three early-stage drug candidates. Key investors include ARK Investment Management and Stanley Druckenmiller's Duquesne Family Office.
6 min read